The confluence of data science and molecular biology fuels expectations among biopharma industry leaders for another year of breakthrough innovation in human therapeutics. More than 70 executives and experts reveal what they are most excited about on the technology front.

Immix collaborates with Israeli research institutions on BCMA-targeted CAR-T therapy. NeoImmuneTech/NIAID alliance could pave way for “animal rule” approval in acute radiation syndrome.

Japan-UK firm is looking to build on a combination of internal and external assets to pursue a more independent business development path in Japan and beyond, in parallel with ongoing discovery and development collaborations.

Adcock Ingram intends to continue seeking partnership deals with multinational firms, after failing to complete two significant acquisitions during its financial year ended 30 June 2022.